Dianthus Therapeutics Inc <DNTH.OQ> expected to post a loss of 87 cents a share - Earnings Preview
Dianthus Therapeutics Inc DNTH.OQ DNTH.O is expected to show a fall in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
The New York City-based company is expected to report a 53.6% decrease in revenue to $864.33 thousand from $1.86 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dianthus Therapeutics Inc is for a loss of 87 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $51.00, about 57.8% above its last closing price of $21.50
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.83 | -0.85 | -0.82 | Beat | 3.4 |
Dec. 31 2025 | -0.88 | -0.85 | -0.81 | Beat | 4.8 |
Sep. 30 2024 | -0.58 | -0.59 | -0.74 | Missed | -24.5 |
Jun. 30 2024 | -0.57 | -0.55 | -0.51 | Beat | 6.5 |
Mar. 31 2024 | -0.44 | -0.44 | -0.54 | Missed | -23.3 |
Dec. 31 2023 | -1.18 | -1.01 | -0.71 | Beat | 29.7 |
Sep. 30 2023 | -0.56 | -0.56 | -3.78 | Missed | -575 |
Jun. 30 2023 | -3.04 | -3.04 | -0.80 | Beat | 73.7 |
This summary was machine generated August 4 at 23:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
